Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06328127 · ClinicalTrials.gov registry record · NA

Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors

A NA study of Hematopoietic Stem Cell Transplant, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
3
Study locations

NCT06328127 is a NA study of Hematopoietic Stem Cell Transplant that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 400 participants, above the 54-participant average among 8 other Hematopoietic Stem Cell Transplant trials with a reported enrollment target (641% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06328127, a NA study of Hematopoietic Stem Cell Transplant, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
3
Study locations

Study Summary

This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared to usual care.

Interventions

  • BEHAVIORAL PATH

Study Locations (3)

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Dana Farber Cancer Institute - Boston

North Carolina

  • Duke Cancer Institute - Durham

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2024-12-17
Est. Completion 2030-05-31
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT06328127

The ClinicalTrials.gov registry entry for NCT06328127 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 54-participant average among 8 other Hematopoietic Stem Cell Transplant trials with a reported enrollment target (641% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hematopoietic Stem Cell Transplant appearing as the primary indexed condition, and to 1 intervention - of which PATH is the first listed.

NCT06328127 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06328127 about?

NCT06328127 is a clinical study titled "Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors". This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared to usual care.

What is the current status of trial NCT06328127?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2024-12-17. Estimated completion is 2030-05-31.

What conditions does trial NCT06328127 study?

This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplant.

What interventions are being tested in trial NCT06328127?

The interventions under investigation include: PATH (BEHAVIORAL).

Who is sponsoring clinical trial NCT06328127?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06328127 being conducted?

This trial has 3 study locations across Florida, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematopoietic Stem Cell Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.